Agency Information Collection Activities: Proposed Collection; Comment Request, 43810-43812 [2019-18113]
Download as PDF
43810
Federal Register / Vol. 84, No. 163 / Thursday, August 22, 2019 / Notices
Bancshares of Texas, Inc., and
indirectly, First National Bank of
Paducah, both of Paducah, Texas.
Board of Governors of the Federal Reserve
System, August 16, 2019.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2019–18059 Filed 8–21–19; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This notice announces the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) approve the proposed
information collection project
‘‘Outcome Measure Harmonization and
Data Infrastructure for Patient Centered
Outcomes Research in Depression.’’
DATES: Comments on this notice must be
received by 60 days after date of
publication.
ADDRESSES: Written comments should
be submitted to: Doris Lefkowitz,
Reports Clearance Officer, AHRQ, by
email at doris.lefkowitz@AHRQ.hhs.gov.
Copies of the proposed collection
plans, data collection instruments, and
specific details on the estimated burden
can be obtained from the AHRQ Reports
Clearance Officer.
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427–1477, or by
emails at doris.lefkowitz@
AHRQ.hhs.gov.
SUPPLEMENTARY INFORMATION:
Proposed Project
Outcome Measure Harmonization and
Data Infrastructure for Patient Centered
Outcomes Research in Depression
The Agency for Healthcare Research
and Quality’s (AHRQ) mission is to
produce evidence to make health care
safer, higher quality, more accessible,
equitable, and affordable, and to work
within the U.S. Department of Health
and Human Services and with other
partners to make sure that the evidence
is understood and used.
In support of this mission, AHRQ
funded a prior project to harmonize the
VerDate Sep<11>2014
16:37 Aug 21, 2019
Jkt 247001
outcome measures collected across
patient registries and routine clinical
practice, with the goals of supporting
the development of a robust data
infrastructure that can consistently and
efficiently collect high-quality data on
outcome measures that are relevant to
patients and clinicians and supporting
patient-centered outcomes research and
quality improvement. Harmonized
outcome measures would also form the
foundation for learning healthcare
systems. Of note, AHRQ has supported
the development of the Outcome
Measures Framework (OMF). The OMF
is a conceptual model for classifying
outcomes that are relevant to patients
and providers across most conditions.
AHRQ, in collaboration with the U.S.
Food and Drug Administration and the
National Library of Medicine, recently
supported an effort to use the OMF as
a content model for developing
harmonized outcome measures in
specific disease areas, including
depression.
Major depressive disorder (MDD) is a
common mental disorder that affects an
estimated 16.2 million adults and 3.1
million adolescents in the United States.
Characterized by changes in mood,
cognitive function, and/or physical
function that persist for two or more
weeks, MDD can reduce quality of life
substantially, impair function at home,
work, school, and in social settings, and
result in increased mortality due to
suicide. MDD also is a major cause of
disability, with an economic burden of
approximately $210.5 billion per year in
the United States.
Despite the burden of MDD and the
availability of treatment, the condition
is often undiagnosed and untreated. In
2016, the U.S. Preventive Services Task
Force recommended screening for
depression in the general adult
population, including pregnant and
postpartum women, and in adolescents.
While routine screening is intended to
improve diagnosis and treatment of
MDD, many questions remain, such as
about the comparative effectiveness of
different treatment approaches, the
incidence of adverse events, when to
add medications for patients who do not
respond to an initial course of
treatment, how and why depression
recurs, and how to classify and treat
treatment-resistant depression. Patient
registries capture a wealth of data on
depression treatment patterns and
outcomes in the United States and could
serve as the foundation for a national
research infrastructure to address these
and other research questions. Yet, a lack
of harmonization in the outcome
measures collected by each registry
makes it challenging, if not impossible,
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
to link and compare data across
registries and related efforts. As
documented in the prior project,
existing registries use different outcome
measures (e.g., remission as defined by
the PHQ–9 vs. HAM–D) and capture
data at different timepoints.
Depression registries offer an
excellent opportunity to demonstrate
the feasibility and value of
implementing the harmonized outcome
measures. Existing registries already
capture some of the harmonized
depression measures for quality
reporting, although at different
timepoints; capture of these measures
and the additional measures at
consistent intervals will enable the
registries to generate more robust data
suitable for research purposes.
AHRQ is now proposing to implement
the harmonized depression outcome
measures developed under the prior
project in two patient registries (the
PRIME Registry and PsychPRO) and a
health system setting. The purpose of
this project is to demonstrate that
capturing the harmonized outcome
measures in the clinical workflow and
submitting these data to different
registries can improve clinical care,
reduce the burden of registry
participation, and increase the utility of
registry data for research purposes. The
objectives of the project are to:
—Demonstrate that collection of the
harmonized outcome measures is
feasible, sustainable, and useful for
clinicians participating in primary
care and mental health patient
registries.
—Demonstrate that collection of the
harmonized outcome measures is
feasible, sustainable, and useful for
clinicians in a health system setting.
Evaluate whether collection of the
harmonized measures increases the
utility of registry data for research
purposes.
The project is being conducted by
AHRQ through its contractor, OM1, Inc.,
pursuant to AHRQ’s statutory authority
to conduct and support research on
healthcare and on systems for the
delivery of such care, including
activities with respect to the quality,
effectiveness, efficiency,
appropriateness and value of healthcare
services and with respect to the
outcomes of such services. 42 U.S.C.
299a(a)(1) and (3).
Method of Collection
To achieve the goals of this project the
following data collections will be
implemented:
(1) Patient Health Questionnaire-9
(PHQ–9)—the PHQ–9 is a brief, 9-item
E:\FR\FM\22AUN1.SGM
22AUN1
43811
Federal Register / Vol. 84, No. 163 / Thursday, August 22, 2019 / Notices
scale that is completed by patients and
reviewed by clinicians at three points
during this project. The scale is used to
measure depression severity, to monitor
changes in depression severity over
time, and to calculate the harmonized
outcome measures for depression
remission, response, recurrence, and
suicide ideation and behavior.
(2) Frequency, Intensity, and Burden
of Side Effects Ratings (FIBSER)—the
FIBSER is a brief, 3-item scale that is
completed by patients and reviewed by
clinicians at three points during this
project. The scale is used to measure the
burden of side effects related to
depression treatment and to calculate
the harmonized outcome measure for
adverse events.
(3) Clinician Survey—the clinician
survey is a brief, 20-question survey that
clinicians in the health system setting
will be asked to complete once at the
conclusion of the project. The survey
captures information on the value of the
harmonized outcome measures for
informing patient care.
Users of the information captured in
this project will fall into two categories:
Clinicians providing care for patients
with depression; and researchers using
the de-identified data to answer a
patient-centered outcomes research
question. AHRQ will receive summary
findings from the data analysis only; no
patient-level data will be shared with
AHRQ.
Estimated Annual Respondent Burden
A key objective of this project is to
demonstrate that the harmonized
outcome measures can be captured as
part of the routine clinical workflow,
with little to no added burden for
clinicians and patients. The harmonized
measures will be calculated primarily
with existing data extracted from
electronic medical records (EMRs).
Extraction of these data will not
represent an additional burden for
clinicians. Patients participating in this
project will be asked to complete up to
two patient-reported outcome
measures—the Patient Health
Questionnaire-9 (PHQ–9) and the
Frequency, Intensity, and Burden of
Side Effects Ratings (FIBSER). Burden is
estimated below for completion of these
instruments by the patient respondent.
Clinicians participating in the health
system component of the project will be
asked to complete the Clinician Survey.
Burden is estimated below for
completion of this survey by the
clinician respondent.
Exhibit 1 shows the estimated
annualized burden hours for the patient
respondent’s time to complete the PHQ–
9 and FIBSER at three time points as
part of this project and for the clinician
respondent to complete the Clinician
Survey at one time point during this
project. The PHQ–9 is a brief, 9-item
scale used to measure depression
severity. The FIBSER is a brief, 3-item
scale used to measure the burden of side
effects related to depression treatment.
The Clinician Survey is a brief, 20question survey designed to assess the
value of the harmonized outcome
measures for informing patient care. The
PHQ–9 is used in routine clinical
practice to screen for depression and
monitor changes in depression severity
over time, as recommended by the U.S.
Preventive Services Task Force. For
some participants in this project,
completion of the PHQ–9 is part of their
existing clinical care routine and does
not represent an extra burden. For
example, the PHQ–9 is already captured
routinely for participants in the
PsychPRO registry. The estimates below
do not include participants in the
PsychPRO registry for that reason.
Because the primary objective of this
project is to determine the feasibility
and value of extracting the relevant data
and calculating the measures, a formal
sample size has not been calculated. We
estimate that the 20 participating sites
in the two patient registries will each
enroll 10 patients, for a total of 200
patients. We estimate that the 5
participating sites at the health system
will each enroll 10 patients, for a total
of 50 patients. We did not include the
PsychPRO enrollment in the PHQ–9
estimates, as the PHQ–9 is already
collected in this registry and does not
represent extra burden. We also do not
anticipate implementing the FIBSER at
the health system sites. Therefore, the
total number of respondents for the
PHQ–9 is estimated at 150, and the total
number of respondents for the FIBSER
is estimated at 200. We anticipate that
three clinicians associated with each of
the five health system sites will
complete the Clinician Survey.
Therefore, the total number of
respondents for the Clinician Survey is
estimated at 15.
Based on existing literature, it is
estimated that completion of the PHQ–
9 takes, on average, 3 minutes, and the
FIBSER takes, on average, 2 minutes to
complete. Participants in the patient
registries will be asked to complete the
PHQ–9 and FIBSER three times over the
course of a year, for a total time of 15
minutes per year. Participants from the
health system will be asked to complete
the PHQ–9 three times over the course
of a year. Clinicians from the health
system sites will be asked to complete
the Clinician Survey once, at the
conclusion of the project; the survey is
designed to be completed in 5 minutes
or less. If 150 respondents complete the
PHQ–9 three times over the course of
one year, the estimated annualized
burden would be 22.5 hours. If 200
respondents complete the FIBSER three
times over the course of one year, the
estimated annualized burden would be
20 hours. If 15 clinicians complete the
Clinician Survey once over the course of
one year, the estimated annualized
burden would be 1.25 hours. The total
estimated annualized burden would be
43.75 hours.
EXHIBIT 1—ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Number of
responses per
respondent
Minutes
per response
Total
burden hours
PHQ–9 .............................................................................................................
FIBSER ............................................................................................................
Clinician Survey ...............................................................................................
150
200
15
3
3
1
3
2
5
22.5
20
1.25
Total ..........................................................................................................
365
........................
........................
43.75
Exhibit 2 shows the estimated cost
burden associated with the respondent’s
time to complete the PHQ–9, FIBSER,
VerDate Sep<11>2014
16:37 Aug 21, 2019
Jkt 247001
and Clinician Survey as part of this
project. The total cost burden to
respondents is estimated at an average
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
of $1,110.93 annually. The duration of
this project is one year.
E:\FR\FM\22AUN1.SGM
22AUN1
43812
Federal Register / Vol. 84, No. 163 / Thursday, August 22, 2019 / Notices
EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN
Number of
respondents
Form name
PHQ–9 .............................................................................................................
FIBSER ............................................................................................................
Clinician Survey ...............................................................................................
Total .................................................................................................................
Total
burden hours
150
200
15
365
Average
hourly
wage rate
22.5
20
1.25
42.5
Total
cost burden
* $24.98
* 24.98
# 39.42
24.98
$562.05
499.6
49.28
1,110.93
* Based on the mean wages for all occupations, 00–0000. May 2018 National Occupational Employment and Wage Estimates. U.S. Department of Labor, Bureau of Labor Statistics. Available at: https://www.bls.gov/oes/current/oes_nat.htm#00-0000.
# Based on the mean wages for Healthcare Practitioners and Technical Occupations, 29–0000. May 2018 National Occupational Employment
and Wage Estimates. U.S. Department of Labor, Bureau of Labor Statistics. Available at: https://www.bls.gov/oes/current/oes_nat.htm#29-0000.
Request for Comments
In accordance with the Paperwork
Reduction Act, comments on AHRQ’s
information collection are requested
with regard to any of the following: (a)
Whether the proposed collection of
information is necessary for the proper
performance of AHRQ’s health care
research and health care information
dissemination functions, including
whether the information will have
practical utility; (b) the accuracy of
AHRQ’s estimate of burden (including
hours and costs) of the proposed
collection(s) of information; (c) ways to
enhance the quality, utility and clarity
of the information to be collected; and
(d) ways to minimize the burden of the
collection of information upon the
respondents, including the use of
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
Dated: August 19, 2019.
Virginia L. Mackay-Smith,
Associate Director.
[FR Doc. 2019–18113 Filed 8–21–19; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Informational Meeting: The Importation
of Infectious Biological Agents,
Infectious Substances and Vectors;
Public Webcast
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of public webcast.
AGENCY:
SUMMARY: The Centers for Disease
Control and Prevention (CDC),
VerDate Sep<11>2014
16:37 Aug 21, 2019
Jkt 247001
Department of Health and Human
Services (HHS), is hosting a public
webcast to address import permit
regulations for infectious biological
agents, infectious substances, and
vectors. Besides CDC, presenters for this
webcast may include representatives
from the U.S. Department of
Transportation, U.S. Department of
Agriculture, Department of Homeland
Security, and U.S. National Authority
for Containment (NAC) of Polioviruses.
DATES: The webcast will be held on
December 4, 2019, from 11 a.m. to 4
p.m. (EST). Registration instructions are
found on the HHS/CDC Import Permit
Program website, https://www.cdc.gov/
cpr/ipp/index.htm.
ADDRESSES: The webcast will be
broadcast from the Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Atlanta, Georgia 30329.
FOR FURTHER INFORMATION CONTACT:
Samuel S. Edwin, Director, Division of
Select Agents and Toxins, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H–21–7,
Atlanta, Georgia 30329. Telephone:
(404) 718–2000.
SUPPLEMENTARY INFORMATION: This
webcast is an opportunity for all
interested parties (e.g., academic
institutions; biomedical centers;
commercial manufacturing facilities;
federal, state, and local laboratories,
including clinical and diagnostic
laboratories; research facilities;
exhibition facilities; and educational
facilities) to obtain specific guidance
and information regarding import
permit regulations for the importation of
infectious biological agents, infectious
substances and vectors. The webcast
will also provide assistance to those
interested in applying for an import
permit from federal agencies within the
United States. Instructions for
registration are found on the HHS/CDC
Import Permit Program website, https://
www.cdc.gov/cpr/ipp/index.htm.
Participants must register by
November 22, 2019. This is a webcastonly event and there will be no on-site
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
participation at the HHS/CDC broadcast
facility.
Dated: August 19, 2019.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2019–18100 Filed 8–21–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–P–0076]
Determination That ZONEGRAN
(Zonisamide) Capsules, 50 Milligrams,
Was Not Withdrawn From Sale for
Reasons of Safety or Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA or Agency) has
determined that ZONEGRAN
(zonisamide) capsules, 50 milligrams
(mg), was not withdrawn from sale for
reasons of safety or effectiveness. This
determination means that FDA will not
begin procedures to withdraw approval
of abbreviated new drug applications
(ANDAs) that refer to this drug product,
and it will allow FDA to continue to
approve ANDAs that refer to the
product as long as they meet relevant
legal and regulatory requirements.
FOR FURTHER INFORMATION CONTACT:
Daniel Gottlieb, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6210,
Silver Spring, MD 20993–0002, 301–
796–6650, Daniel.Gottlieb@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In 1984,
Congress enacted the Drug Price
Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
(the 1984 amendments), which
authorized the approval of duplicate
versions of drug products under an
E:\FR\FM\22AUN1.SGM
22AUN1
Agencies
[Federal Register Volume 84, Number 163 (Thursday, August 22, 2019)]
[Notices]
[Pages 43810-43812]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-18113]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Agency for Healthcare Research and Quality, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces the intention of the Agency for
Healthcare Research and Quality (AHRQ) to request that the Office of
Management and Budget (OMB) approve the proposed information collection
project ``Outcome Measure Harmonization and Data Infrastructure for
Patient Centered Outcomes Research in Depression.''
DATES: Comments on this notice must be received by 60 days after date
of publication.
ADDRESSES: Written comments should be submitted to: Doris Lefkowitz,
Reports Clearance Officer, AHRQ, by email at
[email protected].
Copies of the proposed collection plans, data collection
instruments, and specific details on the estimated burden can be
obtained from the AHRQ Reports Clearance Officer.
FOR FURTHER INFORMATION CONTACT: Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427-1477, or by emails at
[email protected].
SUPPLEMENTARY INFORMATION:
Proposed Project
Outcome Measure Harmonization and Data Infrastructure for Patient
Centered Outcomes Research in Depression
The Agency for Healthcare Research and Quality's (AHRQ) mission is
to produce evidence to make health care safer, higher quality, more
accessible, equitable, and affordable, and to work within the U.S.
Department of Health and Human Services and with other partners to make
sure that the evidence is understood and used.
In support of this mission, AHRQ funded a prior project to
harmonize the outcome measures collected across patient registries and
routine clinical practice, with the goals of supporting the development
of a robust data infrastructure that can consistently and efficiently
collect high-quality data on outcome measures that are relevant to
patients and clinicians and supporting patient-centered outcomes
research and quality improvement. Harmonized outcome measures would
also form the foundation for learning healthcare systems. Of note, AHRQ
has supported the development of the Outcome Measures Framework (OMF).
The OMF is a conceptual model for classifying outcomes that are
relevant to patients and providers across most conditions. AHRQ, in
collaboration with the U.S. Food and Drug Administration and the
National Library of Medicine, recently supported an effort to use the
OMF as a content model for developing harmonized outcome measures in
specific disease areas, including depression.
Major depressive disorder (MDD) is a common mental disorder that
affects an estimated 16.2 million adults and 3.1 million adolescents in
the United States. Characterized by changes in mood, cognitive
function, and/or physical function that persist for two or more weeks,
MDD can reduce quality of life substantially, impair function at home,
work, school, and in social settings, and result in increased mortality
due to suicide. MDD also is a major cause of disability, with an
economic burden of approximately $210.5 billion per year in the United
States.
Despite the burden of MDD and the availability of treatment, the
condition is often undiagnosed and untreated. In 2016, the U.S.
Preventive Services Task Force recommended screening for depression in
the general adult population, including pregnant and postpartum women,
and in adolescents. While routine screening is intended to improve
diagnosis and treatment of MDD, many questions remain, such as about
the comparative effectiveness of different treatment approaches, the
incidence of adverse events, when to add medications for patients who
do not respond to an initial course of treatment, how and why
depression recurs, and how to classify and treat treatment-resistant
depression. Patient registries capture a wealth of data on depression
treatment patterns and outcomes in the United States and could serve as
the foundation for a national research infrastructure to address these
and other research questions. Yet, a lack of harmonization in the
outcome measures collected by each registry makes it challenging, if
not impossible, to link and compare data across registries and related
efforts. As documented in the prior project, existing registries use
different outcome measures (e.g., remission as defined by the PHQ-9 vs.
HAM-D) and capture data at different timepoints.
Depression registries offer an excellent opportunity to demonstrate
the feasibility and value of implementing the harmonized outcome
measures. Existing registries already capture some of the harmonized
depression measures for quality reporting, although at different
timepoints; capture of these measures and the additional measures at
consistent intervals will enable the registries to generate more robust
data suitable for research purposes.
AHRQ is now proposing to implement the harmonized depression
outcome measures developed under the prior project in two patient
registries (the PRIME Registry and PsychPRO) and a health system
setting. The purpose of this project is to demonstrate that capturing
the harmonized outcome measures in the clinical workflow and submitting
these data to different registries can improve clinical care, reduce
the burden of registry participation, and increase the utility of
registry data for research purposes. The objectives of the project are
to:
--Demonstrate that collection of the harmonized outcome measures is
feasible, sustainable, and useful for clinicians participating in
primary care and mental health patient registries.
--Demonstrate that collection of the harmonized outcome measures is
feasible, sustainable, and useful for clinicians in a health system
setting.
Evaluate whether collection of the harmonized measures increases
the utility of registry data for research purposes.
The project is being conducted by AHRQ through its contractor, OM1,
Inc., pursuant to AHRQ's statutory authority to conduct and support
research on healthcare and on systems for the delivery of such care,
including activities with respect to the quality, effectiveness,
efficiency, appropriateness and value of healthcare services and with
respect to the outcomes of such services. 42 U.S.C. 299a(a)(1) and (3).
Method of Collection
To achieve the goals of this project the following data collections
will be implemented:
(1) Patient Health Questionnaire-9 (PHQ-9)--the PHQ-9 is a brief,
9-item
[[Page 43811]]
scale that is completed by patients and reviewed by clinicians at three
points during this project. The scale is used to measure depression
severity, to monitor changes in depression severity over time, and to
calculate the harmonized outcome measures for depression remission,
response, recurrence, and suicide ideation and behavior.
(2) Frequency, Intensity, and Burden of Side Effects Ratings
(FIBSER)--the FIBSER is a brief, 3-item scale that is completed by
patients and reviewed by clinicians at three points during this
project. The scale is used to measure the burden of side effects
related to depression treatment and to calculate the harmonized outcome
measure for adverse events.
(3) Clinician Survey--the clinician survey is a brief, 20-question
survey that clinicians in the health system setting will be asked to
complete once at the conclusion of the project. The survey captures
information on the value of the harmonized outcome measures for
informing patient care.
Users of the information captured in this project will fall into
two categories: Clinicians providing care for patients with depression;
and researchers using the de-identified data to answer a patient-
centered outcomes research question. AHRQ will receive summary findings
from the data analysis only; no patient-level data will be shared with
AHRQ.
Estimated Annual Respondent Burden
A key objective of this project is to demonstrate that the
harmonized outcome measures can be captured as part of the routine
clinical workflow, with little to no added burden for clinicians and
patients. The harmonized measures will be calculated primarily with
existing data extracted from electronic medical records (EMRs).
Extraction of these data will not represent an additional burden for
clinicians. Patients participating in this project will be asked to
complete up to two patient-reported outcome measures--the Patient
Health Questionnaire-9 (PHQ-9) and the Frequency, Intensity, and Burden
of Side Effects Ratings (FIBSER). Burden is estimated below for
completion of these instruments by the patient respondent. Clinicians
participating in the health system component of the project will be
asked to complete the Clinician Survey. Burden is estimated below for
completion of this survey by the clinician respondent.
Exhibit 1 shows the estimated annualized burden hours for the
patient respondent's time to complete the PHQ-9 and FIBSER at three
time points as part of this project and for the clinician respondent to
complete the Clinician Survey at one time point during this project.
The PHQ-9 is a brief, 9-item scale used to measure depression severity.
The FIBSER is a brief, 3-item scale used to measure the burden of side
effects related to depression treatment. The Clinician Survey is a
brief, 20-question survey designed to assess the value of the
harmonized outcome measures for informing patient care. The PHQ-9 is
used in routine clinical practice to screen for depression and monitor
changes in depression severity over time, as recommended by the U.S.
Preventive Services Task Force. For some participants in this project,
completion of the PHQ-9 is part of their existing clinical care routine
and does not represent an extra burden. For example, the PHQ-9 is
already captured routinely for participants in the PsychPRO registry.
The estimates below do not include participants in the PsychPRO
registry for that reason.
Because the primary objective of this project is to determine the
feasibility and value of extracting the relevant data and calculating
the measures, a formal sample size has not been calculated. We estimate
that the 20 participating sites in the two patient registries will each
enroll 10 patients, for a total of 200 patients. We estimate that the 5
participating sites at the health system will each enroll 10 patients,
for a total of 50 patients. We did not include the PsychPRO enrollment
in the PHQ-9 estimates, as the PHQ-9 is already collected in this
registry and does not represent extra burden. We also do not anticipate
implementing the FIBSER at the health system sites. Therefore, the
total number of respondents for the PHQ-9 is estimated at 150, and the
total number of respondents for the FIBSER is estimated at 200. We
anticipate that three clinicians associated with each of the five
health system sites will complete the Clinician Survey. Therefore, the
total number of respondents for the Clinician Survey is estimated at
15.
Based on existing literature, it is estimated that completion of
the PHQ-9 takes, on average, 3 minutes, and the FIBSER takes, on
average, 2 minutes to complete. Participants in the patient registries
will be asked to complete the PHQ-9 and FIBSER three times over the
course of a year, for a total time of 15 minutes per year. Participants
from the health system will be asked to complete the PHQ-9 three times
over the course of a year. Clinicians from the health system sites will
be asked to complete the Clinician Survey once, at the conclusion of
the project; the survey is designed to be completed in 5 minutes or
less. If 150 respondents complete the PHQ-9 three times over the course
of one year, the estimated annualized burden would be 22.5 hours. If
200 respondents complete the FIBSER three times over the course of one
year, the estimated annualized burden would be 20 hours. If 15
clinicians complete the Clinician Survey once over the course of one
year, the estimated annualized burden would be 1.25 hours. The total
estimated annualized burden would be 43.75 hours.
Exhibit 1--Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of
Form name Number of responses per Minutes per Total burden
respondents respondent response hours
----------------------------------------------------------------------------------------------------------------
PHQ-9........................................... 150 3 3 22.5
FIBSER.......................................... 200 3 2 20
Clinician Survey................................ 15 1 5 1.25
---------------------------------------------------------------
Total....................................... 365 .............. .............. 43.75
----------------------------------------------------------------------------------------------------------------
Exhibit 2 shows the estimated cost burden associated with the
respondent's time to complete the PHQ-9, FIBSER, and Clinician Survey
as part of this project. The total cost burden to respondents is
estimated at an average of $1,110.93 annually. The duration of this
project is one year.
[[Page 43812]]
Exhibit 2--Estimated Annualized Cost Burden
----------------------------------------------------------------------------------------------------------------
Number of Total burden Average hourly Total cost
Form name respondents hours wage rate burden
----------------------------------------------------------------------------------------------------------------
PHQ-9........................................... 150 22.5 * $24.98 $562.05
FIBSER.......................................... 200 20 * 24.98 499.6
Clinician Survey................................ 15 1.25 39.42 49.28
Total........................................... 365 42.5 24.98 1,110.93
----------------------------------------------------------------------------------------------------------------
* Based on the mean wages for all occupations, 00-0000. May 2018 National Occupational Employment and Wage
Estimates. U.S. Department of Labor, Bureau of Labor Statistics. Available at: https://www.bls.gov/oes/current/oes_nat.htm#00-0000.
Based on the mean wages for Healthcare Practitioners and Technical Occupations, 29-0000. May 2018 National
Occupational Employment and Wage Estimates. U.S. Department of Labor, Bureau of Labor Statistics. Available
at: https://www.bls.gov/oes/current/oes_nat.htm#29-0000.
Request for Comments
In accordance with the Paperwork Reduction Act, comments on AHRQ's
information collection are requested with regard to any of the
following: (a) Whether the proposed collection of information is
necessary for the proper performance of AHRQ's health care research and
health care information dissemination functions, including whether the
information will have practical utility; (b) the accuracy of AHRQ's
estimate of burden (including hours and costs) of the proposed
collection(s) of information; (c) ways to enhance the quality, utility
and clarity of the information to be collected; and (d) ways to
minimize the burden of the collection of information upon the
respondents, including the use of automated collection techniques or
other forms of information technology.
Comments submitted in response to this notice will be summarized
and included in the Agency's subsequent request for OMB approval of the
proposed information collection. All comments will become a matter of
public record.
Dated: August 19, 2019.
Virginia L. Mackay-Smith,
Associate Director.
[FR Doc. 2019-18113 Filed 8-21-19; 8:45 am]
BILLING CODE 4160-90-P